Poor-prognosis molecular subgroups are associated with a shorter DTI in patients with DLBCL treated with R-CHOP. (A-B) FFP and OS in the study population according to DTI intervals previously defined by Maurer et al.²⁸ (C) DTI frequency distribution according to molecular subgroup. Six outliers with DTI > 100 days are not shown (1 DZsig^pos, 4 GCB, and 1 ABC). (D) Comparison of DTI ratios of molecular subgroups by negative binomial regression using the GCB subgroup as a reference. DTI ratios and 95% CI are shown. (E) Comparison of DTI distribution in patients with DLBCL with DZsig positive (DZsig^pos) tumors based on the presence (HGBCL-DH-BCL2 DZsig^pos, left panel) or absence (DLBCL DZsig^pos, right panel) of a FISH–based diagnosis of HGBCL-DH-BCL2. DTI ratio (95% CI) of HGBCL-DH-BCL2 DZsig^pos relative to DLBCL DZsig^pos was 0.94 (0.67-1.34, P = .74) by negative binomial regression. IQR, interquartile range; UNC, unclassified COO.